FDA-approved1,2Evidence: Large human trialsMetabolic and weight

Tesamorelin1

Also called Egrifta1

Key takeaway

Tesamorelin is a lab-made version of growth hormone-releasing factor, the brain hormone that prompts the pituitary gland to release growth hormone.1 It is FDA-approved as Egrifta for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Drugs@FDA lists its original approval on November 10, 2010.1,2 The label states that it is not indicated for weight loss and that its long-term cardiovascular safety has not been established.1 The approval rests on two randomized, placebo-controlled trials of about 400 adults each, in which visceral abdominal fat fell more with tesamorelin than with placebo.1

Tesamorelin at a glance

What it isA growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.1
FDA statusFDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.1,2
Human evidenceTwo large randomized, double-blind, placebo-controlled trials described in the label, each with a 26-week main phase and a 26-week extension.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is tesamorelin?

Tesamorelin is a lab-made analogue of growth hormone-releasing factor (GHRF), also called growth hormone-releasing hormone (GHRH). The label describes GHRF as a hypothalamic peptide that acts on the pituitary gland to stimulate the release of the body’s own growth hormone.1

In the United States it is the active ingredient of Egrifta, from Theratechnologies, according to Drugs@FDA.2

How does tesamorelin work?

The label states that tesamorelin binds to and stimulates human GRF receptors with potency similar to the natural hormone, prompting the pituitary to make and release growth hormone.1

According to the label, growth hormone has both tissue-building and fat-breaking effects, some of which are carried by IGF-1, a growth factor made in the liver and other tissues.1

The label states that tesamorelin increases IGF-1 levels and that the effects of prolonged IGF-1 elevation are unknown.1

What do human studies show?

The label describes two randomized, double-blind, placebo-controlled trials in adults with HIV, lipodystrophy and excess abdominal fat who were on stable HIV treatment: Study 1 with 412 participants and Study 2 with 404.1

At 26 weeks, visceral abdominal fat measured by CT scan fell by an average of 18% with tesamorelin and rose 2% with placebo in Study 1, and fell 14% with tesamorelin and 2% with placebo in Study 2, according to the label.1

Body weight barely changed in either group, consistent with the label’s statement that the drug is not indicated for weight loss because it has a weight-neutral effect.1

The label reports 26-week completion rates of 80% in Study 1 and 74% in Study 2. The trials excluded people with a history of cancer, an underactive pituitary gland, or previous treatment with insulin or other diabetes medicines.1

What the evidence base contains

  • Large randomized human trial Study 1 (NCT00123253): a randomized, double-blind, placebo-controlled trial in 412 adults with HIV, lipodystrophy and excess abdominal fat, with visceral fat measured by CT scan at 26 weeks.1
  • Large randomized human trial Study 2 (NCT00435136): a randomized, double-blind, placebo-controlled trial of the same design in 404 adults.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is tesamorelin FDA-approved?

Yes. Drugs@FDA lists Egrifta, application BLA022505, with an original approval date of November 10, 2010.2

The Egrifta SV label cited here (DailyMed SPL version 9, published July 31, 2026) states that it is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.1

The label lists these limitations of use: long-term cardiovascular safety has not been established, it is not indicated for weight loss, and there are no data showing that it improves adherence to HIV treatment.1

The label has no boxed warning. It states that tesamorelin is contraindicated in pregnancy, in people with active cancer, with disruption of the hypothalamic-pituitary axis, or with known allergy to it.1

Its warnings cover an increased risk of tumors, elevated IGF-1, fluid retention, glucose intolerance or diabetes, allergic reactions and increased deaths in people with acute critical illness.1

Timeline

  1. FDA approves Egrifta, according to Drugs@FDA.2
  2. DailyMed publishes the Egrifta SV label version cited on this page.1

What is still unknown?

Its long-term cardiovascular safety, which the label says has not been established.1

The effects of keeping IGF-1 levels raised for long periods, which the label says are unknown.1

Whether the reduction in abdominal fat leads to longer-term health benefits: the label’s trials measured fat by CT scan over 26-week phases.1

Its effects outside the approved population: the label’s trials enrolled adults with HIV and lipodystrophy only.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Tesamorelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Tesamorelin are the records PeptideScanner has selected and published, not every registration or paper about Tesamorelin. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Egrifta for HIV-associated abdominal fat. Two randomized, placebo-controlled trials described in the label found larger reductions in visceral abdominal fat than placebo. The label states that it is not indicated for weight loss and that long-term cardiovascular safety has not been established.↗↗

Status sources checked through August 14, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed August 19, 2026 · Review version 1.

Review source snapshots checked August 19, 2026 · Integrity checked August 19, 2026.

A bounded review of two randomized placebo-controlled trials in adults living with HIV and abdominal fat accumulation.↗↗

What the reviewed sources report

The reviewed trials reported reductions in visceral adipose tissue, and the smaller trial also reported a modest reduction in liver fat. These studies do not establish long-term clinical outcomes or effects outside the studied HIV populations.↗↗

What remains unresolved?

  • Do the imaging changes translate into durable clinical benefits, and what are the longer-term effects in the studied population?↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Egrifta SV · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The label covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. It explicitly excludes weight-loss management and says long-term cardiovascular safety has not been established. Label: 1 ↗

Which safety limits matter?

Contraindications include disruption of the hypothalamic-pituitary axis, active malignancy, hypersensitivity and pregnancy. Warnings address neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity and acute critical illness. The label says effects of prolonged IGF-1 elevation are unknown. Label: 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31

Label ZIP SHA-256: 2208a57e39a937407fe40c3d00ff1f8547a7a33e87685d40205cfaba9137cc6c. Extracted XML SHA-256: 280dc13506741337de1fe23ec2d53b3c65241abd9501425611ff106932ca714d.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Tesamorelin?

Manually reviewed August 19, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

A bounded review of two randomized placebo-controlled trials in adults living with HIV and abdominal fat accumulation.12

Bottom line from this bounded source set

The reviewed trials reported reductions in visceral adipose tissue, and the smaller trial also reported a modest reduction in liver fat. These studies do not establish long-term clinical outcomes or effects outside the studied HIV populations.12

Reviewed study record

Twenty-six-week visceral-fat trial

Design

A randomized, placebo-controlled trial assessed computed-tomography visceral adipose tissue and metabolic measures over 26 weeks.1

Population

The trial randomized 412 adults living with HIV who had abdominal fat accumulation during antiretroviral therapy; 86% were men.1

Outcomes reported

Visceral adipose tissue reportedly decreased by 15.2% with tesamorelin and increased by 5.0% with placebo. More participants receiving tesamorelin withdrew because of an adverse event, while the groups did not differ significantly in the reported glycemic measures.1

Limitations

The 26-week trial was limited to adults living with HIV and treatment-associated abdominal fat accumulation and did not establish longer-term clinical outcomes.1

Reviewed study record

Six-month visceral- and liver-fat trial

Design

A double-blind, randomized, placebo-controlled preliminary trial assessed visceral adipose tissue, liver fat, and metabolic measures over six months.2

Population

The single-center trial enrolled 50 antiretroviral-treated adults living with HIV and abdominal fat accumulation; 48 received study treatment.2

Outcomes reported

The reported treatment difference was -42 square centimeters for visceral adipose tissue and -2.9 percentage points for liver fat. The six-month glucose changes were not statistically significant.2

Limitations

The preliminary study was small, single-center, and six months long; the authors stated that further study was needed to determine clinical importance and long-term consequences.2

Reviewed source set

  1. PubMed · 18057338Metabolic effects of a growth hormone-releasing factor in patients with HIV ↗PubMed PMID 18057338 · EFetch XML reviewed 2026-08-19 · payload SHA-256 3e4af3676d797f96af2feabb38705dd17e6e1c1d9011cd116c22b449fb27151c
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa072375. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 25038357Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial ↗PubMed PMID 25038357 · EFetch XML reviewed 2026-08-19 · payload SHA-256 c2d1ad86512b5f64e032d05b54059a7cf624edb143d01fffb7b6ba757962ad1d
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1001/jama.2014.8334. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

The pivotal endpoint measured abdominal fat

FDA’s 2010 assessment describes two 26-week randomized, placebo-controlled trials in HIV-associated lipodystrophy. Their primary endpoint was CT-measured visceral abdominal fat, not cardiovascular events or survival. FDA PDF pp. 3, 7 ↗

More findings, study links and document coverage

Fat reduction did not establish cardiovascular benefit

The review explicitly separates reduced visceral fat from demonstrated cardiovascular benefit. Lipid and body-image results were inconsistent across the two trials, and the body-image instrument had validity concerns. FDA PDF pp. 3, 8, 9 ↗

The extension shows a limit to persistence

Participants switched from tesamorelin to placebo accumulated visceral fat again toward baseline during follow-up. The extension’s switching and selection rules mean it should not be counted as an independent replication of the original trials. FDA PDF pp. 7, 8 ↗

Safety interpretation requires the studied population

The review identifies glucose intolerance, elevated IGF-1 and hypersensitivity concerns. Patients receiving drug treatment for type 2 diabetes were excluded, limiting extrapolation to that broader population. This is a historical assessment, not the current formulation label. FDA PDF pp. 10, 11, 12 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 5 inventoried documents; 4 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

Selected English EMA PDFs from the retained September 15, 2026 title-matched document feed, plus independently retrieved FDA approval-package documents where listed. Candidate entries are not verified product/application matches. This is a bounded inventory, not a complete FDA, national or worldwide source search. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

Remaining work

  • Reconcile the historical NDA with subsequent biologics licensing and formulation-specific labels.
  • Appraise later HIV-associated fatty-liver studies separately from the original abdominal-fat endpoint.

Open versioned document coverage and study pins →

European medicine records · 1 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

104 retrieved · 2 included · 0 excluded · 102 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Tesamorelin"[Title/Abstract] OR "TH9507"[Title/Abstract] OR "Egrifta"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:09:37.410519+00:00 · HTTP 200 · SHA-256 326a7f322d2971be79fe787294e3e1e9ec29a7e30bf4359d8883442985c28c96.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.

Showing 25 of 104 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 25038357 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01263717.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 c2d1ad86512b5f64e032d05b54059a7cf624edb143d01fffb7b6ba757962ad1d.

  2. PubMed 18057338 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT00123253.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 3e4af3676d797f96af2feabb38705dd17e6e1c1d9011cd116c22b449fb27151c.

  3. PubMed 42538058 — not screened: Name-query match awaiting clinical eligibility screening.
  4. PubMed 42419889 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42395176 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42382101 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42160466 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42139091 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42123471 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42018810 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 41966639 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 41598480 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 41545261 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 41490200 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 41476424 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 41138283 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 40510111 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 40397552 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 39813152 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 39746672 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 38905488 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 38416754 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 38197510 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 37806509 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 36845310 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"TESAMORELIN"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:30.408909+00:00 · HTTP 200 · SHA-256 b786af4ac3969df9bb13a5ba03c53fa73fb8db001f1ae4dab0f6f59e2471c8a8.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA BLA022505 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: TESAMORELIN ACETATE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Tesamorelin", "Egrifta"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/002427 — include: EMA feed product Egrifta; reported status: Application withdrawn. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

5 retrieved · 0 included · 0 excluded · 5 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Tesamorelin", "Egrifta"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 13891 — not screened: Title-name match awaiting identity and document review. Questions and answers on the withdrawal of the marketing authorisation application for Egrifta (tesamorelin)
  2. EMA 32433 — not screened: Title-name match awaiting identity and document review. Ferrer Internacional, S.A. withdraws its marketing authorisation application for Egrifta (tesamorelin)
  3. EMA 32484 — not screened: Title-name match awaiting identity and document review. Withdrawal assessment report for Egrifta
  4. EMA 7574 — not screened: Title-name match awaiting identity and document review. Withdrawal letter: Egrifta (tesamorelin)
  5. EMA 37720 — not screened: Title-name match awaiting identity and document review. P/23/2011: EMA decision of 25 January 2011 on the granting of a product specific waiver for tesamorelin (EMEA-001029-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Counci...

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Tesamorelin", "Egrifta"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    ClinicalTrials.gov search

    ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

    25 retrieved · 0 included · 0 excluded · 25 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    "Tesamorelin" OR "Egrifta" OR "TH9507"

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:27:12.284280+00:00 · HTTP 200 · SHA-256 687918fd0446201b309ff4a840ad643c1f2991801019c8b291d00153f845966d.

    • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
    • Other registries, unregistered studies and additional aliases remain outside this query.

    Showing 25 of 25 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. ClinicalTrials.gov NCT01579695 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    2. ClinicalTrials.gov NCT00850564 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    3. ClinicalTrials.gov NCT07481734 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    4. ClinicalTrials.gov NCT02012556 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    5. ClinicalTrials.gov NCT02572323 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    6. ClinicalTrials.gov NCT00123253 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    7. ClinicalTrials.gov NCT00608023 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    8. ClinicalTrials.gov NCT01788462 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    9. ClinicalTrials.gov NCT01632592 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    10. ClinicalTrials.gov NCT06554717 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    11. ClinicalTrials.gov NCT05383456 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    12. ClinicalTrials.gov NCT03150511 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    13. ClinicalTrials.gov NCT02553603 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    14. ClinicalTrials.gov NCT02931474 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    15. ClinicalTrials.gov NCT00795210 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    16. ClinicalTrials.gov NCT01264497 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    17. ClinicalTrials.gov NCT03826160 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    18. ClinicalTrials.gov NCT01388920 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    19. ClinicalTrials.gov NCT00257712 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    20. ClinicalTrials.gov NCT00675506 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    21. ClinicalTrials.gov NCT03226821 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    22. ClinicalTrials.gov NCT01263717 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    23. ClinicalTrials.gov NCT02196831 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    24. ClinicalTrials.gov NCT01591902 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    25. ClinicalTrials.gov NCT03375788 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    Explore status sources, recent additions, and coverage gaps

    Living status brief

    What is the current status of Tesamorelin?

    FDA-approved as Egrifta for HIV-associated abdominal fat. Two randomized, placebo-controlled trials described in the label found larger reductions in visceral abdominal fat than placebo. The label states that it is not indicated for weight loss and that long-term cardiovascular safety has not been established.↗↗

    The cited status sources were checked through August 14, 2026. This answer changes only through the profile’s visible version and correction history.

    Evidence present

    What records are connected here?

    Evidence lanes
    3
    Source years
    14
    Drugs@FDA applications
    1

    These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

    Coverage gaps

    What remains unknown or unsupported?

    PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

    PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

    Explore the Evidence Map and record counts

    Evidence Map v1

    What kinds of records connect to Tesamorelin?

    Compare collection coverage →

    This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

    45Selected dated records
    46Connected citations
    14Populated source years2010–2026
    3/4Record lanes present

    Registered human studies

    Trial composition

    4 of 11 selected trial records include at least one phase value; 4 of 11 include a status value in the retained structured contract.

    90 public history versions connect to 10 of these trial records across 19 submitted years. Open the record-history collection →

    4 exact source-declared trial-publication links connect selected NCT and PMID records. Open the exact graph →

    PhasesPhase 2 2Phase 1 1Phase 3 1
    Status at observationCompleted 2Recruiting 2

    A phase value is unavailable here for 7 selected records; this is not counted as “no phase.”

    A status value is unavailable here for 7 selected records; this is not counted as a trial status.

    PubMed bibliography

    Publication composition

    1 of 21 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

    Publication typesClinical Trial, Phase I 1Journal Article 1Randomized Controlled Trial 1Research Support, Non-U.S. Gov't 1

    Bibliography fields unavailable here for 20 selected records; the records remain visible as metadata observations.

    Regulatory and publication surfaces

    What is structurally connected?

    Drugs@FDA applications
    1
    FDA Federal Register documents
    3
    DailyMed SPL versions
    9
    Canonical profile
    Published
    Profile structured data
    Published
    Linked dated records
    45

    Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

    Profile publication history and record counts
    Trial–publication links · 4

    Exact identifier graph

    4 trial-publication links for Tesamorelin

    Open the full graph →

    These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.

    Source records by collection · 45 dated records

    Research hub

    Explore the Tesamorelin evidence record

    Open all 45 records →
    45Dated records
    3Evidence types
    45Cited public sources
    14Source years

    Change ledger

    Recently changed for Tesamorelin

    Open all 50 events →

    PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

    Record updated

    ClinicalTrials.gov record NCT03150511

    ClinicalTrials.gov posted a newer version of NCT03150511, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 9, 2026
    Evidence lane
    Clinical trials
    Record updated

    ClinicalTrials.gov record NCT07481734

    ClinicalTrials.gov posted a newer version of NCT07481734, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    November 12, 2026
    Evidence lane
    Clinical trials
    Profile status changed

    Tesamorelin profile

    We added a plain-language reader guide with cited answers, re-checked the Egrifta SV label, and added the Drugs@FDA approval record.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Official-source collections

    Source records for Tesamorelin

    Open the full research atlas →
    ClinicalTrials.gov11

    90 public history versions across these dated registry records; status labels apply only to each cited observation.

    1. NCT07481734Registry update November 12, 2026 · current at observation
    2. NCT03150511Registry update November 9, 2026 · current at observation
    3. NCT06554717Registry update May 19, 2026 · current at observation
    Explore all selected trial records →Explore all public record history →
    DailyMed SPL history9

    Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

    1. SPL version 9Published 2026-07-31 · ZIP SHA-256 2208a57e39a9…
    2. SPL version 8Published 2026-01-02 · ZIP SHA-256 93ebb09e6ddb…
    3. SPL version 7Published 2024-12-23 · ZIP SHA-256 c6230de76ac1…
    4. SPL version 6Published 2024-03-14 · ZIP SHA-256 2bc5c98e1c12…
    5. SPL version 5Published 2024-02-02 · ZIP SHA-256 7d01258ee9da…
    Explore all DailyMed label versions →

    Evidence types

    Coverage by source year

    Selected records span January 19, 2010 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

    Continue exploring

    Profiles with overlapping source-year coverage

    Open the research atlas →

    These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

    Organizations and trial records named in cited sources

    Organizations named in cited records

    • U.S. National Library of Medicine1
    • U.S. Food and Drug Administration2
    Dated updates connected to this profile · 45

    Updates connected to this profile

    Open the full cross-source timeline →
    1. Clinical trials

      ClinicalTrials.gov record NCT07481734↗

      PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.↗

    2. Clinical trials

      ClinicalTrials.gov record NCT03150511↗

      PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin.↗

    3. Literature metadata

      PubMed record PMID 41545261↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 41545261 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-01-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

    4. Regulatory

      Tesamorelin DailyMed SPL version 9↗

      DailyMed lists Structured Product Labeling version 9 for the reviewed Tesamorelin label family with a published date of 2026-07-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

    5. Literature metadata

      PubMed record PMID 42419889↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 42419889 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

    6. Literature metadata

      PubMed record PMID 22495074↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 22495074 at 2026-08-10T18:13:32.273Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2012-04-13. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

    7. Clinical trials

      ClinicalTrials.gov record NCT06554717↗

      PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin.↗

    8. Literature metadata

      PubMed record PMID 34006921↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 34006921 at 2026-07-30T16:22:11.959Z. PubMed recorded a metadata revision date of 2026-04-07 and an Entrez history date of 2021-05-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

    9. Literature metadata

      PubMed record PMID 38905488↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38905488 at 2026-07-30T16:22:12.148Z. PubMed recorded a metadata revision date of 2026-04-01 and an Entrez history date of 2024-06-21. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

    10. Clinical trials

      ClinicalTrials.gov record NCT02572323↗

      PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin.↗

    11. Literature metadata

      PubMed record PMID 17571443↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 17571443 at 2026-07-30T16:30:45.652Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

    12. Literature metadata

      PubMed record PMID 21115997↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 21115997 at 2026-07-30T16:30:48.398Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2010-12-01. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗

    Citations

    Sources

    Coverage and sources →

    Numbered markers in the text point here. Each link opens the original public record.

    1. 1
      EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗

      DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

    2. 2
      Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026